CRP to albumin ratio indicates disease activity in juvenile idiopathic arthritis patients: Study

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-08-24 01:00 GMT   |   Update On 2024-08-24 01:00 GMT
Advertisement

A new study by Giulia Di Donato and team found that in individuals with juvenile idiopathic arthritis (JIA), the neutrophil to lymphocyte ratio (NLR) and the C reactive protein to albumin ratio (CAR) may provide evidence of ongoing disease activity. The findings of this study were published in the journal of BMC Rheumatology.

The most common chronic rheumatic condition in children, JIA is a major contributor to both short- and long-term impairment as well as a lower quality of life. The last 20 years have seen the introduction of combination therapy plans and targeted medicines due to increased understanding of JIA etiology. New derivative indicators have emerged as promising biomarkers of systemic inflammation and disease activity in individuals with autoimmune disorders, including rheumatoid arthritis (RA), according to recent scientific research.

Studies on adult RA patients has demonstrated a favorable relationship between disease activity, likelihood of flare, and CRP to CAR. Additionally, number of studies have raised the possibility that NLR and the platelet to lymphocyte ratio (PLR) may serve as supplementary diagnostic tools and inflammatory indicators in RA and other rheumatic disorders. The primary goal of this study was to look at the function of CAR, PLR, and NLR as possible disease activity markers in patients with non-systemic JIA (nsJIA). The second goal was to longitudinally explore the link between CAR, PLR, and NLR with the probability of flare or chronic disease activity over an 18-month period.

A total of 130 nsJIA patients, with 74 patients undergoing active disease and 56 patients undergoing inactive disease, based on Wallace criteria and 62 healthy controls participated in this prospective, cross-sectional study. During follow-up, demographic, clinical, and laboratory data were gathered at baseline (T0), as well as at three, six, twelve, and eighteen months (T1, T2, and T4). The Juvenile Arthritis Disease Activity Score was used to assess disease activity (JADAS-27).

At baseline, there were no differences in NLR or PLR, although CRP and CAR were greater in patients than in controls. But, among the JIA patients, there was no positive link found between CAR, NLR, PLR, and JADAS-27. A generalized estimating equation (GEE) model was implemented to all patients with or without active illness, to better evaluate the function of CAR, NLR, and PLR as indicators of disease activity. This study showed that baseline CAR and NLR levels were indicative of increased disease activity risk at 6-month follow-up (p<0.001). Overall, CAR to NLR value might be strengthened by their combined usage and the study of their trend during follow-up, since increasing CAR levels over time could indicate a disease flare in a short period.

Reference:

Di Donato, G., Attanasi, M., Mariarita d’ Angelo, D., La Bella, S., Di Ludovico, A., Chiarelli, F., & Breda, L. (2024). Associations of C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio with disease activity in patients with juvenile idiopathic arthritis. In BMC Rheumatology (Vol. 8, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1186/s41927-024-00390-x

Tags:    
Article Source : BMC Rheumatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News